DataVXAdvanced Functional MaterialsPaper
journal article·2015-02Open access

Gated Mesoporous Silica Nanoparticles Using a Double‐Role Circular Peptide for the Controlled and Target‐Preferential Release of Doxorubicin in CXCR4‐Expresing Lymphoma Cells

Cristina de la Torre, Isolda Casanova, Gerardo Acosta, Carmen Coll, María José Moreno, Fernando Albericio, Elena Aznar, Ramón Mangues, Miriam Royo, Félix Sancenón, Ramón Martínez‐Máñez

Advanced Functional Materials· Volume 25· Issue 5
Publisher pageOpen full text
Source abstract

Abstract

B‐cell non‐Hodgkin's lymphoma (B‐NHL) is the most frequent malignant lymphoid neoplasm, which has a high degree of relapse and chemoresistance. Thus, strategies to improve currently used therapies are needed. In this context, a new CXCR4‐targeted delivery system is described using mesoporous silica nanoparticles (MSNs) that are loaded with doxorubicin and capped with a derivative of the T22 peptide (P). This design makes full use of the great affinity of the T22 peptide to CXCR4 receptor, which is overexpressed in lymphoma cells. The peptide is able to guide the gated nanoparticle to B‐NHL cells to facilitate MSNs uptake via the CXCR4 receptor. The endocyted P‐capped MSNs are also opened by endosomal proteolytic enzymes to allow intracellular doxorubicin delivery.
Source: crossref · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Glycosylation and Glycoproteins Research · Lymphoma Diagnosis and Treatment · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Centro de Reconocimiento Molecular y Desarrollo Tecnológico (IDM) Unidad Mixta Universitat Politècnica de València‐Universitat de València and CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER‐BBN) Camino de Vera s/n 46022 Valencia Spain

Grup d'Oncogènesi i Antitumorals Institut d'Investigacions Biomèdiques Sant Pau Hospital de Sant Pau and CIBER de Bioingeniería Biomateriales y Nanomedicina Sant Antoni Maria Claret 167Pavelló 11 08025 Barcelona Spain

Institute for Research in Biomedicine Barcelona Science Park‐University of Barcelona and CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER‐BBN) Baldiri Reixac 10 08028 Barcelona Spain

Department of Organic Chemistry Universitat de Barcelona 08028 Barcelona Spain

School of Chemistry Yachay Tech Yachay City of Knowledge Urcuqui Ecuador

Combinatorial Chemistry Unit Barcelona Science Park and CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER‐BBN) Baldiri Reixac 10 08028 Barcelona Spain

Funding

Spanish Government · Generalitat Valenciana · Generalitat de Catalunya · Instituto de Salud Carlos III · MaratóTV3 · CIBER-BBN (Nanomets) · MEC

References (65)

Show source-provided references
1. 10.1002/ange.20060448810.1002/ange.200604488 ↗
2. 10.1002/anie.20060448810.1002/anie.200604488 ↗
3. 10.1039/c002073g10.1039/c002073g ↗
4. 10.1039/c2cs15308d10.1039/c2cs15308d ↗
5. 10.1039/c1cs15246g10.1039/c1cs15246g ↗
6. 10.1039/C2BM00085G10.1039/C2BM00085G ↗
7. 10.1039/c0jm03851b10.1039/c0jm03851b ↗
8. 10.1021/ja028650l10.1021/ja028650l ↗
9. 10.1002/anie.20060340410.1002/anie.200603404 ↗
10. 10.1021/ja806088610.1021/ja8060886 ↗
11. 10.1002/ange.20100506110.1002/ange.201005061 ↗
12. 10.1002/anie.20100506110.1002/anie.201005061 ↗
13. 10.1002/ange.20110796010.1002/ange.201107960 ↗
14. 10.1002/anie.20110796010.1002/anie.201107960 ↗
15. 10.1021/ac202993p10.1021/ac202993p ↗
16. 10.1021/ic302426510.1021/ic3024265 ↗
17. 10.1038/nature0136210.1038/nature01362 ↗
18. 10.1002/ange.20100082710.1002/ange.201000827 ↗
19. 10.1002/anie.20100082710.1002/anie.201000827 ↗
20. 10.1021/nn102922910.1021/nn1029229 ↗
21. 10.1002/adfm.20120134310.1002/adfm.201201343 ↗
22. 10.1002/anie.20110275610.1002/anie.201102756 ↗
23. 10.1021/cm203000u10.1021/cm203000u ↗
24. 10.1002/ange.20080581810.1002/ange.200805818 ↗
25. 10.1002/anie.20080581810.1002/anie.200805818 ↗
26. 10.1021/ja906108510.1021/ja9061085 ↗
27. 10.1021/nn101499d10.1021/nn101499d ↗
28. 10.1021/ja909443910.1021/ja9094439 ↗
29. 10.1002/ange.20120641610.1002/ange.201206416 ↗
30. 10.1002/anie.20120641610.1002/anie.201206416 ↗
31. 10.1002/chem.20120203810.1002/chem.201202038 ↗
32. 10.1038/nmat299210.1038/nmat2992 ↗
33. 10.1002/ange.20100413310.1002/ange.201004133 ↗
34. 10.1002/anie.20100413310.1002/anie.201004133 ↗
35. 10.1002/ppsc.20130021910.1002/ppsc.201300219 ↗
36. 10.1039/C3CC49421G10.1039/C3CC49421G ↗
37. 10.1002/chem.20140014810.1002/chem.201400148 ↗
38. 10.1016/j.ijpharm.2013.04.01410.1016/j.ijpharm.2013.04.014 ↗
39. 10.1039/c3cp50916h10.1039/c3cp50916h ↗
40. 10.1021/nn405726910.1021/nn4057269 ↗
41. 10.1002/adfm.20130298810.1002/adfm.201302988 ↗
42. 10.1021/nn204102q10.1021/nn204102q ↗
43. 10.1002/adfm.20120131610.1002/adfm.201201316 ↗
44. 10.1002/anie.20100506110.1002/anie.201005061 ↗
45. 10.1021/ja312004m10.1021/ja312004m ↗
46. 10.1002/anie.20130255710.1002/anie.201302557 ↗
47. 10.1200/JCO.2005.09.13110.1200/JCO.2005.09.131 ↗
48. 10.1016/S1470-2045(11)70235-210.1016/S1470-2045(11)70235-2 ↗
49. 10.1177/10732748120190030510.1177/107327481201900305 ↗
50. 10.1111/j.1365-2141.2008.07037.x10.1111/j.1365-2141.2008.07037.x ↗
51. 10.1034/j.1600-0609.2000.90147.x10.1034/j.1600-0609.2000.90147.x ↗
52. 10.1182/blood-2002-03-093810.1182/blood-2002-03-0938 ↗
53. 10.1016/j.leukres.2013.10.01610.1016/j.leukres.2013.10.016 ↗
54. 10.1002/path.444610.1002/path.4446 ↗
55. 10.1111/j.1747-0285.2008.00681.x10.1111/j.1747-0285.2008.00681.x ↗
56. 10.1128/JVI.73.9.7489-7496.199910.1128/JVI.73.9.7489-7496.1999 ↗
57. Unzueta U. · Int. J. Nanomed. · 2012 · 7 · 4533
58. 10.1016/S0968-0896(98)00061-310.1016/S0968-0896(98)00061-3 ↗
59. 10.1016/j.bbamem.2006.11.00210.1016/j.bbamem.2006.11.002 ↗
60. Alsayed Y. · Blood · 2007 · 109 · 270810.1182/blood-2006-07-035857 ↗
61. 10.1182/blood-2006-05-02484410.1182/blood-2006-05-024844 ↗
62. 10.1158/1078-0432.CCR-07-222310.1158/1078-0432.CCR-07-2223 ↗
63. 10.1189/jlb.120365210.1189/jlb.1203652 ↗
64. 10.1007/s00059-011-3470-310.1007/s00059-011-3470-3 ↗
65. 10.1111/j.2042-7158.2012.01567.x10.1111/j.2042-7158.2012.01567.x ↗